Reglan

Quick links to important sections

Reglan

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Reglan

Quick Facts

Property Description
Active ingredient Metoclopramide hydrochloride
Form Tablet, oral solution, injection
Pharmacological class Prokinetic agent, Antiemetic
General purpose Relieving digestive distress and nausea
Origin Synthetic compound

Metoclopramide: Definition and Pharmacological Classification

Reglan is a specific prescription-only medication that contains the active substance Metoclopramide, a single-ingredient product typically formulated as Metoclopramide hydrochloride. This synthetic compound is clinically recognized for its unique dual classification as both a prokinetic agent and an antiemetic. Pharmacologically, Metoclopramide functions as a dopamine D2 receptor antagonist, particularly targeting the central chemoreceptor trigger zone. This dual functionality means the medicine is designed to affect both the mechanics of digestion and the neurological signals that cause the sensation of sickness.

Composition, Origin, and Available Forms

Metoclopramide is manufactured in several dosage form(s) to ensure effective administration, including the traditional tablet and the oral solution for oral administration, as well as a sterile injection for rapid delivery via the Intravenous (IV) or Intramuscular (IM) route. The injection form, composed of the active substance in an aqueous solution, offers a key differentiating factor, allowing for immediate administration when oral intake is difficult. This versatility in form supports the drug's use in various clinical contexts where speed of action is necessary.

General Purpose and Therapeutic Focus

The overall therapeutic focus of a prokinetic agent like Reglan is centered on the relief of digestive distress and the alleviation of the sensation of nausea and vomiting. Its purpose is to stimulate the motility of the upper gastrointestinal tract, leading to gastric emptying acceleration. Concurrently, its antiemetic function suppresses the central impulse to vomit. This combined physiological action ensures the digestive tract moves contents more efficiently while calming the body’s involuntary impulse to vomit.

What side effects are possible with Reglan?

Possible Side Effects and Safety Information

The official safety profile for metoclopramide (Reglan) is characterized by a spectrum of adverse reactions classified by frequency and system-organ class, based on regulatory documentation from authorities such as the FDA and EMA. Understanding these classifications is key to defining the medicine’s risk profile.


Adverse Reaction Classifications

Side effects are grouped by the bodily systems they affect, with significant risks associated with the Nervous System.

Frequency Example Adverse Reaction System-Organ Class
Very Common Somnolence (Drowsiness) Nervous System
Common Diarrhea, Depression Gastrointestinal / Psychiatric
Uncommon Bradycardia, Galactorrhea Cardiac / Endocrine
Rare Convulsions, Anaphylaxis Nervous System / Immune System

Serious Safety Concerns and Risk Patterns

The most clinically significant safety concern documented in regulatory labeling is the risk of Tardive Dyskinesia (TD), a serious movement disorder. This risk is explicitly tied to prolonged use, particularly when therapy extends beyond the recommended short-term duration (typically 12 weeks). Acute extrapyramidal symptoms, such as dystonia, are reported to occur more frequently in the first 24 to 48 hours following treatment initiation.

Other serious adverse reactions include Neuroleptic Malignant Syndrome (NMS), a potentially fatal syndrome, and severe cardiovascular events, including cardiac arrest, primarily following intravenous administration.

Population-Specific Notes and Restrictions

Safety documents specify heightened susceptibility to adverse effects in certain groups. Children and young adults have an increased risk of acute extrapyramidal symptoms, while older adults face a higher risk of developing TD. Furthermore, the use of metoclopramide is formally contraindicated in patients with conditions such as gastrointestinal hemorrhage, mechanical obstruction, or a known history of epilepsy.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the officially documented clinical presentations and required emergency actions for metoclopramide (Reglan) overdose, as stated in regulatory prescribing information.

Domain Documented Manifestations and Risks
Common Presentation Overdose frequently presents with central nervous system (CNS) effects, including drowsiness, confusion, disorientation, lethargy, and diarrhea. Extrapyramidal reactions (uncontrolled muscle movements, such as dystonia) are also documented.
Severe Outcomes Officially documented severe or life-threatening outcomes include seizures, death, and Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex. Methemoglobinemia, a specific hematological finding, has been reported, particularly in neonates following overdose exposure.
Required Action Immediate medical attention or contact with emergency services is required for any suspected overdose. Urgent care must be sought for the onset of life-threatening symptoms, such as high fever or muscle stiffness associated with NMS.

Official Management Principles Management of a metoclopramide overdose is primarily symptomatic and supportive, as regulatory documents state that no specific antidote for the drug itself is known. Anticholinergic agents or benzodiazepines are described as potential supportive measures for managing extrapyramidal reactions that may occur. Methylene blue is documented for the reversal of methemoglobinemia caused by overdose.

Therapeutic Uses of Reglan

What Reglan Treats: Main Uses and Benefits

Reglan (metoclopramide) is approved for specific clinical scenarios in adults to help manage certain symptoms. The medication is indicated for the short-term (4-12 weeks) management of symptomatic gastroesophageal reflux (GERD) in patients who have not responded adequately to conventional therapies. It is also used for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (delayed stomach emptying), which can include difficulty swallowing and a feeling of early fullness.

Additional clinical uses for injectable forms include the control of postoperative nausea and vomiting and assistance in certain diagnostic procedures. The potential benefit for patients is targeted symptom relief from digestive issues such as nausea, vomiting, and persistent heartburn or fullness after meals.


Quick Fact: May assist in managing symptoms related to diabetic gastroparesis.

Eligibility and Restrictions for Use

Eligibility for Reglan (Metoclopramide) — Official Regulatory Profile

Official regulatory documents define strict limitations on who can and cannot use metoclopramide. Use is Contraindicated in several groups due to severe risk, including:

  • Patients with gastrointestinal hemorrhage, mechanical obstruction, or perforation, as stimulating motility could be dangerous.
  • Individuals with a history of tardive dyskinesia induced by metoclopramide or antipsychotics, or those with Parkinson's disease or epilepsy.
  • Patients with a pheochromocytoma (adrenal gland tumor) due to the risk of hypertensive crisis.
  • Infants under 1 year of age due to an increased risk of neurological side effects.

Use is Restricted for other populations. The treatment duration is strictly limited for all patients, typically to 12 weeks (FDA) or 5 days (EMA), because the risk of serious, irreversible movement disorders increases with prolonged use. Patients with severe renal or hepatic impairment are eligible only for conditional use and require a mandatory dosage reduction. Caution is also advised in the elderly and those with certain cardiac conditions or depression. Use is generally not recommended during breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents classify metoclopramide (Reglan) interactions based on pharmacodynamic and pharmacokinetic effects, resulting in specific constraints for co-administration. Combination is formally contraindicated with Dopaminergic Agonists (e.g., Levodopa) and should be avoided with other medications that increase the risk of Extrapyramidal Reactions (EPS).

Pharmacodynamic and Substance Interactions

Metoclopramide is anticipated to have additive effects with central nervous system (CNS) depressants, including alcohol, which can potentiate sedation. Anticholinergic drugs and Narcotic Analgesics (Opioids) are documented to have an antagonistic effect, reducing metoclopramide's action on gastrointestinal motility. Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is restricted due to the formal risk of hypertensive crisis.

Pharmacokinetic and Exposure Changes

Metoclopramide's metabolism is influenced by the CYP2D6 enzyme. Co-administration with strong CYP2D6 inhibitors (such as Fluoxetine or Quinidine) is documented to increase metoclopramide exposure (AUC/Cmax) and requires a mandatory dosage reduction. Conversely, metoclopramide can alter the absorption of other oral drugs; it increases Cyclosporine exposure but decreases oral Digoxin exposure. Diabetic patients may require adjustment to the timing or dosage of insulin due to metoclopramide’s effect on gastric emptying.

Population-Specific Restrictions

Mandatory dosage reduction is required in specific populations, including patients with Renal Impairment (creatinine clearance le 60 mL/min) and Hepatic Impairment, as regulatory information states clearance is reduced, increasing the risk of accumulation.

Mechanism of Action

Central Suppression of the Vomiting Reflex

Metoclopramide's action involves both the Central Nervous System (CNS) and the peripheral Enteric Nervous System. In the CNS, the molecule functions as an antagonist of Dopamine D2 receptors and Serotonin 5-HT3 receptors within the Chemoreceptor Trigger Zone (CTZ). By blocking these targets, the drug modulates the afferent signals that activate the adjacent medullary vomiting center, leading to the inhibition of the activation of the medullary vomiting center.


⬆️ Augmenting Upper Gastrointestinal Motility

The prokinetic action is primarily peripheral. Metoclopramide acts as an agonist on Serotonin 5-HT4 receptors in the Enteric Nervous System. This 5-HT4 agonism significantly enhances the local release of the neurotransmitter acetylcholine. This increased cholinergic tone boosts the strength and coordination of smooth muscle contractions in the upper GI tract, resulting in increased velocity of gastric transit and enhanced Lower Esophageal Sphincter (LES) muscle contractility.

Dosage and Administration Information

How Reglan (Metoclopramide) Is Used: Official Administration Guidelines

Metoclopramide must be used according to established protocols for its approved forms and routes of administration, which include oral (tablets, solution), intravenous (IV), and intramuscular (IM) injection.

Standard Dosing and Timing

Administration Detail Official Guideline
Standard Oral Dose 10 mg per dose, repeated up to three or four times daily, depending on the approved indication.
Maximum Duration Must be limited to the shortest possible time. Maximum 12 weeks for chronic use; maximum 5 days for acute use.
Timing (Oral) Doses are typically taken 30 minutes before each meal and at bedtime.
Dose Interval A minimal interval of 6 hours must be respected between any two administrations, even if the prior dose was rejected.

Procedural and Population Adjustments

For intravenous administration, doses must be given as a slow injection (over at least 1–2 minutes) or diluted and infused slowly. For doses greater than 10 mg, dilution in 50 mL of a compatible solution is required for infusion.

Dose adjustments are mandatory for specific patient groups. Guidelines specify that the total dose be reduced (e.g., by 50% or more) in patients diagnosed with moderate or severe renal impairment or severe hepatic impairment. Similarly, a lower starting dose should be considered for older adults based on their renal and hepatic function.

Recent Clinical Evidence

Reglan: Recent Clinical Evidence

Clinical research and regulatory reviews define the role of metoclopramide (Reglan) primarily as a treatment for gastrointestinal motility disorders and for nausea and vomiting.

Efficacy in Gastrointestinal Conditions

Metoclopramide is the only medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetic gastroparesis, a condition causing delayed stomach emptying. Clinical trials have reported that metoclopramide can accelerate gastric emptying in these patients. Studies examining the relief of associated symptoms such as nausea, vomiting, fullness, and bloating have reported symptomatic improvement compared to placebo.

For gastroesophageal reflux disease (GERD), metoclopramide is generally considered for short-term use in adults who have not responded to conventional therapies, such as proton pump inhibitors. Research has shown that the medication can increase the tone of the lower esophageal sphincter, which may reduce the backward flow of stomach contents.

Anti-emetic Use

The drug is also indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV). Its anti-emetic action is explored in the central nervous system. In the context of PONV prophylaxis, studies have demonstrated a modest effect in preventing early vomiting episodes.

Safety and Duration of Use

Recent regulatory advisories emphasize that metoclopramide should typically not be used for more than 12 weeks. This limitation is based on the risk of developing tardive dyskinesia (TD), a serious and potentially irreversible movement disorder. The risk of TD is considered to increase with the duration of treatment and total cumulative dosage. Special consideration is given to patient groups with increased risk, including the elderly, women, and individuals with diabetes or certain hepatic/renal impairments.

Frequently Asked Questions (FAQ)

Common questions about Reglan (FAQ)

Q: What is the main reason doctors prescribe Reglan?

A: According to official regulatory documents, the primary approved uses for metoclopramide include the short-term treatment of symptomatic gastroesophageal reflux (GERD). It is also used in the management of symptoms associated with diabetic gastroparesis.

Q: Is Reglan considered a first-line treatment for gastroparesis?

A: Regulatory guidance indicates that the drug's use is generally restricted to a short duration. It is used for the treatment of certain symptoms of diabetic gastroparesis when the patient's response to other management measures has been insufficient.

Q: Can Reglan be used for general stomach pain relief?

A: The drug is officially indicated for specific motility conditions such as diabetic gastroparesis and certain types of symptomatic reflux. It is not generally indicated in regulatory documents for the relief of non-specific or general stomach pain.

Q: Is Reglan the same kind of drug as erythromycin?

A: Official classification states that metoclopramide is a dopamine antagonist and a prokinetic agent. Erythromycin, however, is classified as an antibiotic; they belong to different primary therapeutic classes.

Q: Does Reglan have a sedative effect?

A: Drowsiness or sedation is listed as a very common or frequent adverse reaction in regulatory documents.

Q: Can Reglan cause anxiety or feelings of restlessness?

A: Common central nervous system side effects described in official labeling include feelings of anxiety and restlessness (akathisia).

Q: What are the most common mental side effects of Reglan?

A: Regulatory documents list common psychiatric adverse effects. These can include depression, restlessness (akathisia), anxiety, and insomnia (difficulty sleeping).

Q: Is it true that Reglan has a risk for tardive dyskinesia?

A: Yes, metoclopramide carries a Black Box Warning from the FDA regarding this risk. Tardive dyskinesia is described as a condition characterized by potentially irreversible, involuntary movements, particularly of the face and tongue.

Q: How quickly does Reglan start working after taking it?

A: According to regulatory documents summarizing its pharmacology, the onset of action after taking the drug orally is generally described as occurring within 30 to 60 minutes.

Q: If I miss a dose of Reglan, what should I do?

A: Official instructions described in regulatory documents state that if a dose is missed, the approach is to skip that dose entirely. Regulatory guidance specifies that a minimal interval of six hours must be respected between any two administrations.

Q: How long does the effect of Reglan last in the body?

A: The duration of the drug's effect is related to its half-life, which is a measure of how long it takes for half of the drug to be eliminated from the body. In healthy adults, the elimination half-life is typically described as approximately 5 to 6 hours.

Q: Is Reglan safe to take for more than a few weeks?

A: Official documents describe a risk for developing involuntary movements (tardive dyskinesia) with longer-term use. Because of this safety concern, regulatory agencies require that the drug be used for the shortest possible time, often not exceeding a maximum duration like 12 weeks for chronic conditions.

Q: Can Reglan be taken by people who have diabetes?

A: One of the official regulatory indications for metoclopramide is the short-term relief of symptoms associated with diabetic gastroparesis.

Q: Is Reglan appropriate for people with kidney problems?

A: Regulatory documents state that dose adjustments are required for patients who have moderate to severe renal (kidney) impairment. Furthermore, the drug is contraindicated (meaning it should not be used) in patients who have uncorrected severe renal impairment.

Q: Are there certain heart conditions where Reglan is not recommended?

A: The drug is contraindicated in patients with conditions such as phaeochromocytoma. Warnings also exist regarding the potential for QTc interval prolongation, which is a factor that can affect heart rhythm.

Q: Does Reglan interact with common antacids like Tums?

A: Regulatory documents do not generally list specific antacid brand names. However, they note that the drug may interact with medications that affect gastric motility, absorption, or central nervous system effects.

Q: Can Reglan be taken with antibiotics like ciprofloxacin?

A: Regulatory warnings exist regarding co-administration with other drugs that can prolong the QTc interval. Co-administration with other drugs that can prolong the QTc interval is described as potentially increasing the risk of heart rhythm issues.

Q: What happens if Reglan is taken with SSRI antidepressants?

A: Regulatory documents warn about the potential for metoclopramide to interact with serotonergic drugs, which include SSRI antidepressants. Regulatory documents warn that the combination could potentially increase the risk of Serotonin Syndrome.

Q: Is there a concern about drinking alcohol while using Reglan?

A: Regulatory documents advise against the concomitant use of alcohol due to the potential for increased sedative effects.

Q: Does Reglan change the effect of birth control pills?

A: Metoclopramide may theoretically affect the absorption of other oral medications. However, regulatory documents generally state that no dose adjustment is considered necessary for oral contraceptives.

Q: Is Reglan safe for people over the age of 65?

A: According to official product information, older adults may face an increased risk of certain side effects, such as involuntary muscle movements (extrapyramidal symptoms). Regulatory documents note that a lower starting dose should be considered for this population, based on factors like kidney and liver function.

Q: Is Reglan only for adults or is it used in children too?

A: Metoclopramide is approved for use in both adults and, for specific indications, in children and adolescents. However, its use in pediatric populations is restricted due to a higher risk of extrapyramidal disorders.

Q: What is the classification of Reglan?

A: Metoclopramide is officially classified as a substituted benzamide. Therapeutically, it is known as a dopamine receptor antagonist and a prokinetic agent (meaning it promotes movement in the gastrointestinal tract).

Q: Can Reglan cause confusion or dizziness?

A: Dizziness and confusion are listed among the potential adverse reactions affecting the central nervous system in regulatory documents.

Q: What should I watch out for when taking Reglan?

A: Official warnings describe monitoring for signs of serious adverse events. These include involuntary movements (tardive dyskinesia), severe reactions like neuroleptic malignant syndrome (NMS), and depression.

Q: Is the long-term use of Reglan supported by research?

A: Regulatory agencies require that use be limited to the shortest duration possible, typically not exceeding 12 weeks, due to safety concerns regarding the development of involuntary movements. The majority of research focuses on short-term relief.

Q: What is the typical timeframe for seeing benefits from Reglan?

A: Clinical trial data summarized in regulatory documents indicate that the drug is used for short-term symptom relief. Efficacy is often evaluated within a few weeks of starting treatment.

Q: Do studies suggest that Reglan is generally well-tolerated?

A: Regulatory documents summarize clinical trial data by listing the frequency of adverse reactions. Common reactions, such as drowsiness, fatigue, and restlessness, are frequently reported.

Q: Is Reglan often prescribed for heartburn or GERD symptoms?

A: One of the approved uses for metoclopramide is the short-term treatment of symptomatic, documented gastroesophageal reflux (GERD). This indication is typically reserved for cases that have not responded to standard therapy.

Q: Is Reglan a controlled substance?

A: Regulatory bodies in the United States do not classify metoclopramide (Reglan) as a controlled substance. This designation relates to drugs with a high potential for abuse.

Q: Does Reglan affect blood pressure?

A: Regulatory documents list changes in blood pressure, including both hypotension (low blood pressure) and hypertension (high blood pressure), as possible adverse reactions.

Q: Is it possible to become dependent on Reglan?

A: Regulatory documents describe the potential for the body to experience withdrawal symptoms, such as anxiety or nervousness, if treatment is stopped suddenly, particularly after prolonged use.

Q: Can Reglan cause problems with vision?

A: Visual disturbances are listed as a possible, though less common, adverse reaction in official product labeling.

Q: Is there a Black Box Warning for Reglan?

A: Yes, the U.S. Food and Drug Administration (FDA) requires a Black Box Warning for metoclopramide. This is the strongest warning the FDA mandates for prescription drugs and is primarily related to the risk of tardive dyskinesia.

Q: What if I experience unusual muscle movements while on Reglan?

A: Regulatory documents describe the possibility of involuntary muscle movements, known as extrapyramidal symptoms (EPS) or tardive dyskinesia. Official warnings describe these movements, such as tremors or slow, erratic movements, as potential side effects.

Q: Does Reglan affect stomach acid production?

A: The primary mechanism of action described in regulatory documents is to augment upper gastrointestinal motility and inhibit the vomiting reflex. It is not classified as a drug intended to reduce stomach acid production, unlike PPIs or H2 blockers.

Q: Can people with liver disease use Reglan?

A: Regulatory documents require dose adjustments for people with severe hepatic (liver) impairment. Official guidance, for example, often recommends reducing the total daily dose by half for this patient population.

Q: What research is available on Reglan use during pregnancy?

A: Official labeling provides data from studies of pregnant women and states that there are no adequate and well-controlled studies. Generally, the drug is used during pregnancy only if clearly needed.

Q: Is Reglan approved for treating morning sickness?

A: The official regulatory indications for metoclopramide do not explicitly include the treatment of morning sickness (nausea and vomiting of pregnancy). Approved uses are limited to specific gastrointestinal conditions.

Q: Does Reglan interact with any common pain relievers?

A: Regulatory documents warn about co-administering metoclopramide with medications that affect the central nervous system. This may include certain pain relievers, due to the risk of additive sedative effects.

Q: Can Reglan cause weight change?

A: Regulatory documents list both weight increase and weight decrease among the reported, though less common, adverse reactions.

Q: What is the half-life of Reglan?

A: The elimination half-life of metoclopramide in healthy adults is described as approximately 5 to 6 hours. This value represents the time required for the concentration of the drug in the body to be reduced by half.

Q: Is Reglan available as a generic medicine?

A: The drug metoclopramide is available in generic form, as well as under the brand name Reglan. The generic form is reviewed by regulatory agencies to ensure it meets the same quality standards as the brand-name product.

Q: Can Reglan affect sleep patterns?

A: Insomnia (difficulty sleeping), drowsiness, and fatigue are listed among the common adverse reactions in official labeling.

Q: Why is Reglan sometimes used before medical procedures?

A: Metoclopramide is indicated for the prevention of postoperative nausea and vomiting. It is also sometimes used to facilitate medical procedures that require small bowel intubation.

Q: What is the risk of withdrawal symptoms if Reglan is stopped suddenly?

A: Regulatory documents describe that after prolonged use, abruptly stopping metoclopramide may be associated with symptoms. These withdrawal symptoms can include headache, nervousness, or anxiety.

Q: Does Reglan interact with herbal supplements like St. John's Wort?

A: Regulatory documents generally advise caution with other agents that affect the central nervous system. Advice regarding St. John's Wort, a serotonergic agent, would be considered under the warning for Serotonin Syndrome risk.

Q: What are the official approved uses of Reglan?

A: Approved uses for metoclopramide generally include the short-term treatment of symptomatic gastroesophageal reflux (GERD) and the management of diabetic gastroparesis.

Q: Is it normal to feel tired when starting Reglan?

A: Fatigue and drowsiness are listed as very common adverse reactions in regulatory documentation.

Q: Can I take Reglan if I have a history of seizures?

A: The drug is contraindicated (not recommended for use) in patients with a history of seizure disorder. The contraindication is due to the described potential for increasing seizure frequency.

Q: What are the ingredients in a Reglan tablet?

A: The active ingredient in Reglan is metoclopramide hydrochloride. Regulatory labels also list inactive ingredients, known as excipients, which are necessary to form the tablet but do not contribute to the drug's effect.

How should Reglan be stored and disposed of?

Official Storage and Disposal Requirements

Official labeling defines strict conditions for the storage and disposal of Reglan (metoclopramide) tablets and injection.

Requirement Area Official Rule Summary
Required Environment Store at 20 C to 25 C (68 F to 77 F) (Controlled Room Temperature) and protect from light (light sensitive).
Packaging Rules Tablets must be kept in the original, tightly closed bottle. Injection vials must remain in the carton until use.
Stability & Handling The oral solution must be used within one month of opening the bottle. Single-dose injection vials must have the unused portion discarded. Inspect the injection before use for discoloration or particulates.
Child Safety Keep Reglan and all medicines out of the sight and reach of children (mandatory requirement).
Disposal Instructions Do not dispose of unused or expired medicine via wastewater or household waste. Consult a pharmacist for proper disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Reglan found in:

A-Z Index: